Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
L-carnitine peritoneal dialysis solution versus standard glucose solution in CAPD patients with ESRD
2006-005298-23Phase 2Terminated
- Sponsor
- Iperboreal Pharma
- Start
- Apr 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of levocarnitine in end-stage kidney disease (ESKD) and chronic kidney disease (CKD) (2 arms), sponsored by Iperboreal Pharma. Primary endpoint: Primary efficacy endpoint. Started Apr 2007; status: terminated.
02
Drugs
levocarnitine
03
Conditions
end-stage kidney disease (ESKD)chronic kidney disease (CKD)
Beyond the preview
Go deeper on 2006-005298-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-005298-23.